Grants and Contributions

Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unprecedented opportunity for automatic design of new drugs with much faster pace and much lower cost, igniting hopes to discovery drugs for diseases where no medicines have been found yet.

Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unprecedented opportunity for automatic design of new drugs with much faster pace and much lower cost, igniting hopes to discovery drugs for diseases where no medicines have been found yet.

The specific objectives of the project are to: Develop and formalize the structure of the paramedics regulatory consortia group; Reach consensus on 4 national levels of practitioners (common designation); Develop nationally agreed on common scopes of practice for each of the 4 practitioner license levels; Finalize and agree on a competency profile that will serve as the national standard, and therefore a common inter-provincial standard for licensure; Develop an inter-jurisdictional exam for entry to practice levels for the current designations of Primary Care Paramedic (PCP) and Advanced Care Paramedic (ACP); PCP and ACP cover 80% of the Canadian Paramedics); Develop a framework for a common national assessment of internationally trained Paramedics; Research issues of common interest.

This project aims to enhance the engagement of Canadians, especially youth (aged between 12 and 18), in Canada’s international development efforts towards the achievement of the SDGs and FIAP, with a focus on gender equality and the empowerment of women and girls.

This project aims to empower Canadian small and medium organizations (SMOs) and their partners in the Global South.

The project seeks to engage Canadian CSOs in the humanitarian sector in study tours and learning exchanges.

This project demonstrates Canada’s commitment to fulfilling G7 and G20 obligations to “expand Canadian diplomacy and leadership on global issues” (as per the PM’s Mandate Letter to the Minister of Foreign Affairs); and directly complement IGA’s chairmanship of the Global Partnership (GP)’s Biological Security Working Group (BSWG) and the GP’s Chemical, Biological, Radiological and Nuclear Working Group (CBRNWG), serving as tangible and dynamic examples of Canada’s contribution to the G7 and GP Presidencies in 2018.

The company plans to do a detailed market study of the Canadian market for candy and snack food products through the youth resource employed.

Heart failure is a devasting and chronic disease affecting an estimated 600,000 Canadians. It is characterized by episodes of severe shortness of breath and leg swelling resulting in frequent, prolonged hospital admissions and often high rate of hospital readmission.

According to Health Canada, in 2019, about 11% of Canadians aged 20 and over were living with diabetes, and the rate has been increasing.